Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Santaris Pharma brings in $12mm through sale of convertible bonds

Executive Summary

Santaris Pharma AS has raised DKK70mm ($12mm) through the two-tranche sale of convertible bonds to current shareholders Sunstone Capital, Novo, Gilde Healthcare, Forbion Capital Partners, LD, Global Life Science Venture, Seventures, and company management. The proceeds will be used to continue development of Phase II Miravirsen for hepatitis C and to work on the company's Locked Nucleic Acid (LNA) platform, which helps identify drug candidates for infectious diseases, inflammation, cardiometabolic conditions, cancer, and rare genetic disorders.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Convertible Debt
    • Private Placement

Related Companies